Alpine Associates Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Alpine Associates Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.8M	Buy	+925,000	New	+$13M	1.17%	36

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Alpine Associates Management's DAWN Position: Q1 2026 in Review

Alpine Associates Management opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 925,000 shares worth $19.8M. The stake represents 1.17% of the portfolio and ranks #36 among its holdings.

206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Alpine Associates Management held 925,000 shares of Day One Biopharmaceuticals worth $19.8M as of Q1 2026.
Day One Biopharmaceuticals was a new Alpine Associates Management position in Q1 2026.
Day One Biopharmaceuticals made up 1.17% of Alpine Associates Management's portfolio in Q1 2026, its #36 holding.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Alpine Associates Management's 13F filing for Q1 2026, filed 21 Apr 2026.